EA202090691A1 - Лечение заболевания, опосредованного гмк - Google Patents

Лечение заболевания, опосредованного гмк

Info

Publication number
EA202090691A1
EA202090691A1 EA202090691A EA202090691A EA202090691A1 EA 202090691 A1 EA202090691 A1 EA 202090691A1 EA 202090691 A EA202090691 A EA 202090691A EA 202090691 A EA202090691 A EA 202090691A EA 202090691 A1 EA202090691 A1 EA 202090691A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
mmc
disease caused
smcs
diagnostics
Prior art date
Application number
EA202090691A
Other languages
English (en)
Inventor
Стюарт Александр Кук
Себастиан Шефер
Вэй Вэнь Лим
Бенджамин Вэй Мин Ын
Original Assignee
Сингапур Хэлс Сервисес Пте. Лтд.
Нэшнл Юниверсити Оф Сингапур
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сингапур Хэлс Сервисес Пте. Лтд., Нэшнл Юниверсити Оф Сингапур filed Critical Сингапур Хэлс Сервисес Пте. Лтд.
Publication of EA202090691A1 publication Critical patent/EA202090691A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

Предложены диагностика, лечение и профилактика заболеваний и состояний, связанных с дисфункцией гладкомышечных клеток (ГМК), посредством ингибирования опосредованной IL-11 передачи сигналов.
EA202090691A 2017-10-12 2018-10-12 Лечение заболевания, опосредованного гмк EA202090691A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1716733.9A GB201716733D0 (en) 2017-10-12 2017-10-12 Treatment of SMC mediated disease
PCT/EP2018/077940 WO2019073057A1 (en) 2017-10-12 2018-10-12 TREATMENT OF SMC MEDIATED DISEASE

Publications (1)

Publication Number Publication Date
EA202090691A1 true EA202090691A1 (ru) 2020-12-07

Family

ID=60419332

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090691A EA202090691A1 (ru) 2017-10-12 2018-10-12 Лечение заболевания, опосредованного гмк

Country Status (14)

Country Link
US (2) US11780898B2 (ru)
EP (1) EP3694876A1 (ru)
JP (2) JP2020536921A (ru)
KR (1) KR20200093533A (ru)
CN (1) CN111655724A (ru)
AU (1) AU2018347676A1 (ru)
BR (1) BR112020007139A2 (ru)
CA (1) CA3077368A1 (ru)
CL (1) CL2020000966A1 (ru)
EA (1) EA202090691A1 (ru)
GB (1) GB201716733D0 (ru)
MX (1) MX2020003668A (ru)
PH (1) PH12020550255A1 (ru)
WO (1) WO2019073057A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201902419D0 (en) * 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
US20200397816A1 (en) * 2019-06-24 2020-12-24 The Trustees Of Indiana University Methods to treat inflammatory and smooth muscle cell proliferation disorders
KR20230150287A (ko) * 2021-02-26 2023-10-30 바이엘 악티엔게젤샤프트 비정상적 자궁 출혈의 치료에 사용하기 위한 il-11 또는 il-11ra의 억제제
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060019890A1 (en) 2004-01-15 2006-01-26 Kapoun Ann M Method for treating cardiac remodeling following myocardial injury
EP2091551B1 (en) 2006-11-03 2020-01-15 Alba Therapeutics Corporation Method of treating asthma
US8182814B2 (en) * 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US8518888B2 (en) * 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
KR101133769B1 (ko) 2011-04-18 2012-04-09 한국생명공학연구원 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
AU2014214530B2 (en) 2013-02-07 2014-10-16 Csl Limited IL-11R binding proteins and uses thereof
WO2017049349A1 (en) * 2015-09-25 2017-03-30 Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research A method of treatment and prophylaxis
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
WO2018187485A1 (en) * 2017-04-04 2018-10-11 The George Washington University Combination therapy for treating cancer
JP2020518643A (ja) * 2017-05-05 2020-06-25 ヒューブファーマＨｕｖｅｐｈａｒｍａ 抗炎症剤としての官能化されたサッカライド

Also Published As

Publication number Publication date
KR20200093533A (ko) 2020-08-05
CL2020000966A1 (es) 2021-02-26
MX2020003668A (es) 2020-08-20
CN111655724A (zh) 2020-09-11
PH12020550255A1 (en) 2020-12-07
AU2018347676A1 (en) 2020-05-21
JP2020536921A (ja) 2020-12-17
WO2019073057A1 (en) 2019-04-18
US20190241637A1 (en) 2019-08-08
JP2023113725A (ja) 2023-08-16
US20240141004A1 (en) 2024-05-02
US11780898B2 (en) 2023-10-10
CA3077368A1 (en) 2019-04-18
EP3694876A1 (en) 2020-08-19
GB201716733D0 (en) 2017-11-29
BR112020007139A2 (pt) 2020-10-20

Similar Documents

Publication Publication Date Title
EA202090691A1 (ru) Лечение заболевания, опосредованного гмк
EA202090019A1 (ru) Спироциклические индолины в качестве модуляторов il-17
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EA201791977A1 (ru) Способы лечения патологических непроизвольных движений
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
EA201490030A1 (ru) Соединения, ингибирующие металлоферменты
EA201690007A1 (ru) Соединения, ингибирующие металлоферменты
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
EA201892008A1 (ru) Соединения и способы лечения неврологических и сердечно-сосудистых состояний
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
EA202091020A1 (ru) Замещенные имидазопиридинамиды и их применение
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
WO2017066712A3 (en) Modulators of telomere disease